Ejection Fraction
Introduction
Background
Ejection fraction (EF) is a crucial clinical parameter that quantifies the efficiency of the heart's pumping action. It represents the percentage of blood ejected from the left ventricle with each contraction. While the provided research directly discusses Left Ventricular Fractional Shortening (LVFS) as an echocardiographic trait, ejection fraction is a closely related and widely utilized measure of left ventricular systolic function. Both measures provide insight into the heart's ability to effectively pump oxygenated blood to the body.
Biological Basis
The heart functions as a muscular pump to circulate blood throughout the body. The left ventricle is the primary chamber responsible for propelling oxygenated blood into the aorta and onward to the systemic circulation. Ejection fraction is calculated based on the volume of blood in the left ventricle at the end of its relaxation phase (diastole) and the volume remaining after its contraction phase (systole). A healthy heart efficiently contracts to expel a substantial portion of its blood volume. Cardiac dimensions such as left ventricular chamber size, wall thickness, and mass, which are also assessed through echocardiography, play a fundamental role in the heart's overall pumping capacity and are integral to cardiovascular health. [1]
Clinical Relevance
Ejection fraction is a cornerstone in the diagnosis, prognosis, and management of various cardiovascular conditions, particularly heart failure. A reduced ejection fraction signifies impaired heart function and is a key indicator of systolic heart failure. Abnormalities in left ventricular chamber size, wall thickness, and mass are strongly linked to the development of high blood pressure and clinical cardiovascular disease, including stroke and heart failure. [1] Echocardiographic traits, such as those reflecting left ventricular function, serve as important intermediate phenotypes in the pathway from cardiovascular risk factors to overt disease. [1] These traits are known to be heritable and have been associated with specific genetic loci. [1] For example, single nucleotide polymorphisms (SNPs) like rs10511550, rs10504543, rs10510001, and rs10510000 have been associated with Left Ventricular Fractional Shortening (LVFS) [1] underscoring a genetic component to cardiac pumping efficiency.
Social Importance
Given its critical role in assessing heart health, ejection fraction holds significant social importance. Cardiovascular diseases, including heart failure, are leading causes of morbidity and mortality globally, placing a substantial burden on healthcare systems and significantly impacting quality of life. Early detection and appropriate management of abnormal ejection fraction can guide therapeutic interventions, improve patient outcomes, and potentially mitigate the societal impact of heart disease. Furthermore, understanding the genetic underpinnings of ejection fraction and related cardiac traits can contribute to the development of personalized medicine approaches and targeted preventive strategies.
Methodological and Statistical Constraints
The studies faced limitations in statistical power, particularly for detecting genetic effects that explain a small proportion of phenotypic variation. While there was over 90% power to detect associations explaining 4% or more of variation at a stringent alpha level, more modest effects might have been missed due to the sample size and extensive multiple testing. [1] Furthermore, the ability to replicate previously reported findings was constrained by the partial coverage of genetic variation on the Affymetrix 100K gene chip, limiting a comprehensive assessment of known candidate genes. [1] This suggests that some observed associations, despite appearing moderately strong, could represent false positives, highlighting the need for independent validation. [1]
The lack of genome-wide significance for any observed association, even with extensive statistical testing, does not definitively rule out genetic influences on echocardiographic measures relevant to ejection fraction. [1] The analyses were considered exploratory, especially for specific candidate genes, due to the limited coverage of the 100K GeneChip. [1] Additionally, a relatively liberal genotyping call rate threshold of 80% was adopted to be more inclusive in reporting associations, which could potentially introduce variability or reduce confidence in some findings. [1] The ultimate value of identified novel genetic associations hinges on their successful replication in independent populations. [2]
Phenotypic Measurement and Temporal Variability
The characterization of echocardiographic traits, including measures related to ejection fraction, involved averaging observations across multiple examinations spanning up to twenty years. [1] While this approach aimed to better characterize the phenotype over time and reduce regression dilution bias, it introduced potential misclassification due to the use of different echocardiographic equipment over this extended period. [1] Such long-term averaging also assumes a consistent influence of genes and environmental factors across a wide age range, which might not hold true, potentially masking age-dependent genetic effects on cardiac function. [1]
Generalizability and Gene–Environment Interactions
A significant limitation is that the study population consisted solely of individuals of white, European descent. [1] Consequently, the generalizability of the findings regarding genetic associations with ejection fraction to other ethnic or racial groups remains unknown, necessitating further research in diverse populations. [1] Genetic variants are known to influence phenotypes in a context-specific manner, often modulated by environmental factors, which highlights the importance of diverse study cohorts. [1]
The study did not specifically investigate gene-environment interactions, which are crucial for a comprehensive understanding of complex traits like ejection fraction. [1] Prior research has shown that associations of genes like ACE and AGTR2 with cardiac traits can be influenced by environmental factors such as dietary salt intake. [1] Without exploring these interactions, the full picture of how genetic predispositions manifest in varying environmental contexts for ejection fraction cannot be fully elucidated, leaving potential confounders unaddressed. [1]
Variants
Genetic variations play a crucial role in determining the structural and functional characteristics of the heart, including its pumping efficiency, known as ejection fraction. Variants within genes involved in fundamental cellular processes, such as protein quality control, chromatin remodeling, and nutrient transport, are essential for maintaining the health and performance of cardiomyocytes. For instance, the rs5760061 variant is located in regions encompassing both the DERL3 and SMARCB1 genes. DERL3 (Derlin 3) is integral to the endoplasmic reticulum-associated degradation (ERAD) pathway, ensuring the proper disposal of misfolded proteins, a process critical for preventing cellular stress that can impair heart muscle function. Concurrently, SMARCB1 is a component of the SWI/SNF chromatin remodeling complex, which regulates gene expression vital for heart development and adaptation to stress . Similarly, variants like rs6546120, associated with SLC1A4 and LINC02245, may influence the activity of SLC1A4, which encodes a neutral amino acid transporter essential for cardiomyocyte metabolism and energy supply. The non-coding RNAs LINC00964 (with variant rs34866937) and LINC02245, along with the pseudogene RN7SKP120, are thought to exert regulatory control over various gene networks, collectively impacting the heart's ability to maintain optimal ejection fraction .
Other variants affect genes involved in cell cycle control, structural integrity, and critical signaling pathways, all of which are paramount for proper cardiac function. For example, the rs181881383 variant near TUSC1 (Tumor Suppressor Candidate 1) and rs807029 in LZTS2 (Leucine Zipper Tumor Suppressor 2) are associated with genes that regulate cell growth and maintain the cytoskeleton. Disruptions in these processes can lead to abnormal cardiac remodeling or weakened muscle structure, directly compromising the heart's ability to effectively pump blood . Furthermore, the rs6466832 variant, found near CADPS2 (Calcium Dependent Secretion Activator 2) and CICP17, highlights the importance of calcium signaling. CADPS2 is involved in calcium-dependent exocytosis, and precise calcium handling is a fundamental mechanism underpinning cardiomyocyte contraction and relaxation, thereby directly influencing the heart's ejection fraction and overall mechanical efficiency .
Metabolic health, the integrity of the extracellular matrix, and proper developmental signaling pathways are also critical determinants of cardiac function. The rs2645430 variant, associated with FDFT1 (Farnesyl-Diphosphate Farnesyltransferase 1), is relevant to cholesterol biosynthesis, a pathway whose dysregulation can contribute to atherosclerosis and increased cardiac workload, indirectly affecting ejection fraction. Similarly, the rs74133262 variant near HMCN1 (Hemicentin 1) is important because HMCN1 encodes an extracellular matrix protein crucial for maintaining the structural framework of the myocardium; defects can lead to fibrosis or weakened heart muscle . Non-coding RNAs like LINC02101 (with variant rs2964186) and the genomic locus GS1-204I12.4 may modulate these metabolic and structural processes. Additionally, the ROBO2P1 pseudogene, linked to rs35205176, is related to ROBO2, a gene involved in developmental signaling pathways that are essential for proper cardiac formation and adaptation throughout life, ultimately impacting the heart's long-term health and pumping capability .
There is no information about 'ejection fraction' in the provided context.
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs34866937 | LINC00964 | left ventricular ejection fraction measurement left ventricular diastolic function measurement fractional shortening ejection fraction measurement left ventricular systolic function measurement |
| rs5760061 | DERL3, SMARCB1 | left ventricular systolic function measurement ejection fraction measurement heart failure left ventricular ejection fraction measurement electrocardiography |
| rs6546120 | SLC1A4, LINC02245 | ejection fraction measurement left ventricular systolic function measurement fractional shortening |
| rs181881383 | RN7SKP120 - TUSC1 | ejection fraction measurement |
| rs807029 | LZTS2 | ejection fraction measurement cerebral cortex area attribute |
| rs2645430 | FDFT1 | ejection fraction measurement BMI-adjusted waist-hip ratio BMI-adjusted waist circumference neuroticism measurement monocyte count |
| rs2964186 | LINC02101 | ejection fraction measurement |
| rs74133262 | GS1-204I12.4 - HMCN1 | ejection fraction measurement |
| rs6466832 | CADPS2 | ejection fraction measurement |
| rs35205176 | CICP17 - ROBO2P1 | ejection fraction measurement |
Genetic Underpinnings
Ejection fraction, often assessed through left ventricular fractional shortening, exhibits a significant genetic component, with moderate-to-strong heritability estimates observed for various echocardiographic traits. Genome-wide association studies (GWAS) have identified several single nucleotide polymorphisms (SNPs) associated with left ventricular fractional shortening, including rs10504591, rs10511550, and rs10504543. These findings suggest that the trait is influenced by multiple genetic variants, reflecting a complex polygenic architecture rather than a single gene effect. Candidate genes such as NRG2, which may have pleiotropic effects on ventricular remodeling, and MEF2C, a critical regulator of cardiac morphogenesis, further illustrate the intricate genetic basis of cardiac function. [1]
Lifestyle and Modifiable Risk Factors
Beyond genetic predispositions, several environmental and lifestyle factors significantly influence ejection fraction. Modifiable risk factors such as smoking, body weight, and dietary habits contribute to overall cardiovascular health and, consequently, cardiac function. Furthermore, comorbidities like hypertension, characterized by elevated systolic and diastolic blood pressure, are fundamental to the pathogenesis of left ventricular remodeling and clinical cardiovascular disease, which directly impacts ejection fraction. The management of these conditions, including treatment for hypertension, plays a crucial role in maintaining optimal cardiac performance. [1]
Interplay of Genes, Environment, and Aging
The relationship between genetic susceptibility and environmental influences is complex, with genetic variants often interacting with external factors in a context-specific manner to affect cardiac phenotypes. For instance, the impact of genes like ACE and AGTR2 on left ventricular mass has been observed to vary with dietary salt intake, highlighting how environmental triggers can modulate genetic predispositions. Additionally, age-related physiological changes are important contributors to variations in ejection fraction, with studies indicating that age-dependent gene effects may exist, which can be obscured when observations are averaged across broad age ranges. [1]
Cardiac Mechanics and Function
Ejection fraction, often represented by left ventricular (LV) fractional shortening, is a crucial measure of the heart's pumping efficiency, reflecting its ability to eject blood from the left ventricle with each beat. [1] This metric is derived from echocardiographic measurements, specifically the LV internal dimension in diastole (LVDD) and systole (LVSD), which characterize the heart's size at its most relaxed and contracted states, respectively. [1] A healthy heart maintains an optimal balance in these dimensions, ensuring effective circulation of blood throughout the body.
Alterations in these cardiac dimensions, including changes in LV wall thickness (LVWT) and LV mass (LVM), are indicative of left ventricular remodeling. [1] This remodeling process can represent a fundamental disruption in cardiac homeostasis and is recognized as a significant factor in the development of various cardiovascular diseases, such as high blood pressure, stroke, and heart failure. [1] Therefore, monitoring LV fractional shortening and related echocardiographic traits provides critical insights into cardiac health and disease progression.
Genetic Influences on Cardiac Traits
Echocardiographic traits, including those reflecting ejection fraction, are known to be heritable, meaning genetic factors significantly contribute to individual variations in heart structure and function. [3] Genome-wide association studies (GWAS) and linkage analyses have identified various single nucleotide polymorphisms (SNPs) associated with these traits, such as rs10504543 and rs10511762 linked to LV diastolic and systolic dimensions, highlighting specific genomic regions that influence cardiac characteristics. [1] These genetic variations can impact the efficiency of the heart's pumping action and its overall physiological capacity.
Beyond specific SNPs, several genes have been implicated in influencing cardiac structure and function. For instance, MEF2C has been identified as a critical regulator of cardiac morphogenesis, playing a fundamental role in the development of the heart. [1] Another gene, NRG2 (neuregulin-2), is associated with vascular flow and has shown proximity to regions influencing LV mass, suggesting potential pleiotropic effects on both ventricular and vascular remodeling. [1] Such genetic insights are essential for understanding the inherited predispositions to cardiac conditions.
Molecular and Cellular Regulation of Myocardial Health
At the molecular and cellular level, the identified genes orchestrate complex pathways critical for myocardial health. The transcription factor MEF2C is deeply involved in a range of cellular functions within cardiomyocytes, including extracellular matrix remodeling, the precise handling of ions, and metabolic processes. [1] Disturbances in these pathways, which are essential for maintaining the heart's structural integrity and contractile function, can directly impair the heart's ability to pump efficiently and contribute to cardiac dysfunction.
Furthermore, NRG2, a member of the epidermal growth factor (EGF) family, exerts its effects by binding to ErbB receptors, initiating signaling cascades that influence both ventricular and vascular remodeling. [1] This intricate receptor-ligand interaction plays a role in cellular growth, differentiation, and survival, highlighting its importance in maintaining the integrity and function of cardiac and vascular tissues. Additionally, MAPK1 and its associated MAPK signaling pathway are recognized for their role in mediating cellular responses, including those in muscle tissues, further emphasizing the complex molecular networks underlying cardiovascular performance. [1]
Pathophysiological Consequences and Cardiovascular Health
Reduced ejection fraction, or left ventricular fractional shortening, is a hallmark of impaired cardiac function and a significant indicator in the pathogenesis of clinical cardiovascular disease (CVD), including the progression to overt heart failure. [1] The heart's response to chronic stress or injury often involves maladaptive remodeling, where changes in LV chamber size and wall thickness occur. These changes represent a disruption of normal homeostatic mechanisms, leading to a less efficient pump and placing individuals at higher risk for adverse cardiovascular events. [1]
Echocardiographic dimensions, alongside measures of vascular health such as brachial artery flow-mediated dilation (FMD), serve as crucial intermediate phenotypes in the pathway from common risk factors to overt CVD. [1] Endothelial dysfunction, assessed via brachial artery FMD, is itself a fundamental component of atherosclerosis and a precursor to widespread cardiovascular issues. [4] Understanding the biological underpinnings of these interconnected traits provides comprehensive insight into disease mechanisms and potential avenues for therapeutic intervention to mitigate systemic consequences.
Clinical Relevance of Ejection Fraction
Ejection fraction, a critical measure of cardiac pump function, particularly of the left ventricle, provides essential insights into cardiovascular health and disease prognosis. While the specific term "ejection fraction" is not directly utilized in the provided research, its assessment is closely mirrored by related echocardiographic traits such as left ventricular fractional shortening (LVFS), which serves as a key indicator of left ventricular systolic function . The clinical relevance of evaluating this measure spans diagnosis, risk stratification, and guiding therapeutic strategies for various cardiovascular conditions.
Clinical Assessment and Risk Prediction
Ejection fraction, as reflected by measures like left ventricular fractional shortening, plays a fundamental role in the clinical assessment of cardiac function and the prediction of cardiovascular disease (CVD) risk. Abnormalities in left ventricular systolic function are closely linked to the development of clinical CVD, including the pathogenesis of heart failure and stroke . In community-based cohorts, such as the Framingham Heart Study, echocardiographic measurements like LVFS are routinely assessed to identify individuals at elevated risk, allowing for early intervention and potentially informing prevention strategies .
The diagnostic utility further extends to identifying specific predictors of conditions like congestive heart failure. For instance, left ventricular dilatation, which can be a consequence of impaired systolic function, is a recognized risk factor for congestive heart failure, particularly in elderly populations. [5] Therefore, evaluating ejection fraction helps clinicians stratify risk and personalize care, especially for individuals susceptible to developing or progressing existing cardiovascular morbidities.
Prognostic Value and Disease Management
The prognostic value of ejection fraction is significant in determining the long-term outlook for patients with established cardiovascular diseases, especially heart failure. Left ventricular systolic function directly influences the outcome of congestive heart failure in elderly persons. [6] Monitoring changes in ejection fraction (or LVFS) over time is therefore crucial for tracking disease progression, assessing the efficacy of ongoing treatments, and making informed decisions regarding therapeutic adjustments.
This continuous monitoring allows for personalized management strategies, ensuring that interventions are tailored to the individual's cardiac response. The ability to predict outcomes based on ejection fraction provides clinicians with a powerful tool for counseling patients, setting realistic expectations, and optimizing care to improve quality of life and reduce morbidity and mortality associated with progressive heart disease. [6]
Genetic Insights and Personalized Approaches
Ejection fraction, as an indicator of left ventricular function, is influenced by genetic factors, contributing to its heritability within families. Echocardiographic traits, including left ventricular fractional shortening, exhibit modest-to-strong heritability, suggesting a genetic predisposition to variations in cardiac structure and function . Genome-wide association studies (GWAS) have begun to identify specific genetic loci associated with these traits; for example, rs10511550 has been linked to left ventricular fractional shortening .
Understanding the genetic underpinnings of ejection fraction can pave the way for more personalized medicine approaches. By identifying individuals with genetic predispositions to impaired cardiac function, clinicians may be able to implement targeted screening programs, early preventive measures, or tailored pharmacologic strategies before overt disease manifests. This genetic risk stratification represents a promising avenue for enhancing precision in cardiovascular care and improving long-term patient outcomes .
Longitudinal Cohort Studies and Heritability of Cardiac Dimensions
Large-scale cohort studies have been instrumental in understanding the population-level characteristics and genetic underpinnings of left ventricular (LV) dimensions and function. The Framingham Heart Study (FHS), a long-standing community-based cohort, conducted a genome-wide association study (GWAS) to investigate the genetic determinants of echocardiographic dimensions, including LV mass, diastolic and systolic dimensions, wall thickness, and fractional shortening (a measure related to ejection fraction). [1] Researchers averaged echocardiographic traits across four examinations over a twenty-year period to better characterize phenotypes and mitigate regression dilution bias, though this approach could introduce misclassification due to varying equipment and potentially mask age-dependent gene effects. [1] This extensive longitudinal data from the FHS has allowed for the estimation of modest-to-strong heritabilities (ranging from 0.30 to 0.52) for various echocardiographic traits, highlighting the significant genetic influence on cardiac structure and function in the population. [1]
Further insights from the Framingham Heart Study and the Cardiovascular Health Study (CHS) have illuminated the distribution and categorization of echocardiographic measurements within general populations. These studies have established height- and sex-specific classifications and validated their prospective utility in predicting cardiovascular outcomes. [7] For example, analyses of the FHS have detailed the prognostic implications of echocardiographically determined left ventricular mass, linking it to various adverse cardiovascular events. [8] Such comprehensive population-based studies provide a foundation for understanding the natural history and variability of cardiac dimensions over the lifespan.
Epidemiological Associations and Cardiovascular Risk
Population studies have consistently demonstrated strong epidemiological associations between echocardiographic parameters and the incidence and prevalence of cardiovascular diseases. Elevated left ventricular mass, for instance, has been identified as a significant independent risk factor for stroke in elderly cohorts, including participants from the Framingham Heart Study. [9] Beyond stroke, echocardiographic predictors, such as left ventricular mass, have been shown to predict the six-to-seven-year incidence of coronary heart disease, congestive heart failure, and overall mortality in elderly populations, as evidenced by findings from the Cardiovascular Health Study. [10] These findings underscore the critical role of cardiac structural and functional assessments as powerful prognostic indicators within diverse demographic groups.
Moreover, the impact of left ventricular structure extends to the incidence of hypertension, with studies like the Framingham Heart Study demonstrating a clear link between specific LV structural characteristics and the subsequent development of high blood pressure. [11] Genetic epidemiological studies, such as the GWAS in the Framingham Heart Study, have also begun to uncover specific genetic variants associated with these traits, identifying single nucleotide polymorphisms (SNPs) like rs1379659 near SLIT2 for LV diastolic dimension, rs10504543 near KCNB2 for LV systolic dimension, and rs10498091 for LV mass, which contribute to the polygenic architecture of cardiac dimensions and their related disease risks. [1] These genetic insights complement traditional epidemiological findings, offering a deeper understanding of the biological pathways influencing cardiovascular health.
Methodological Approaches and Generalizability Limitations
The methodologies employed in population studies of echocardiographic dimensions often involve sophisticated statistical and genetic approaches, alongside careful consideration of sample characteristics. The Framingham Heart Study's GWAS utilized generalized estimating equations (GEE) and family-based association tests (FBAT) to analyze multivariable-adjusted trait residuals, effectively accounting for correlation among related individuals within nuclear families. [1] The study analyzed 70,987 autosomal SNPs from the Affymetrix 100K SNP GeneChip in a sample of up to 1238 related middle-aged to elderly men and women, with phenotypes carefully adjusted for covariates such as age, sex, height, weight, smoking status, blood pressure, and hypertension treatment. [1] These rigorous methodological considerations are crucial for identifying robust associations between genetic variants and echocardiographic traits.
However, the generalizability of findings from such studies is an important consideration. The Framingham Heart Study's sample, for instance, was predominantly composed of individuals of white, European descent, which limits the direct applicability of its genetic findings to other ethnic populations. [1] While the study of Japanese populations has provided some cross-ethnic comparisons regarding left ventricular mass and blood pressure changes, broader cross-population investigations are necessary to fully understand ancestry-specific effects and geographic variations in cardiac dimensions and function. [12] Future research must address these limitations to ensure that insights into the population genetics and epidemiology of cardiac traits are inclusive and representative of global diversity.
References
[1] Vasan RS, et al. "Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study." BMC Med Genet, 2007.
[2] Wilk, J. B. et al. "Framingham Heart Study genome-wide association: results for pulmonary function measures." BMC Med Genet, vol. 8, suppl. 1, 2007, p. S10.
[3] Arnett DK, Hong Y, Bella JN, Oberman A, Kitzman DW, Hopkins PN, et al. "Sibling correlation of left ventricular mass and geometry in hypertensive African Americans and whites: the HyperGEN study." Am J Hypertens, vol. 14, 2001, pp. 1226-1230.
[4] Benjamin EJ, Larson MG, Keyes MJ, Mitchell GF, Vasan RS, Keaney JF Jr, et al. "Clinical correlates and heritability of flow-mediated dilation in the community: the Framingham Heart Study." Circulation, vol. 109, 2004, pp. 613-619.
[5] Gottdiener JS, Arnold AM, Aurigemma GP, Polak JF, Tracy RP, Kitzman DW, Gardin JM, Rutledge JE, Boineau RC. "Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study." J AM COLL CARDIOL, vol. 35, 2000, pp. 1628-1637.
[6] Gottdiener JS, McClelland RL, Marshall R, Shemanski L, Furberg CD, Kitzman DW, Cushman M, Polak J, Gardin JM, Gersh BJ, Aurigemma GP, Manolio TA. "Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study." Ann Intern Med, vol. 137, 2002, pp. 631-639.
[7] Vasan, R.S., et al. "Distribution and categorization of echocardiographic measurements in relation to reference limits: the Framingham Heart Study: formulation of a height- and sex-specific classification and its prospective validation." Circulation, vol. 96, 1997, pp. 1863-1873.
[8] Levy, D., et al. "Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study." NEW ENGL J MED, vol. 322, 1990, pp. 1561-1566.
[9] Bikkina, M., et al. "Left ventricular mass and risk of stroke in an elderly cohort. The Framingham Heart Study." JAMA, vol. 272, 1994, pp. 33-36.
[10] Gardin, J.M., et al. "M-mode echocardiographic predictors of six- to seven-year incidence of coronary heart disease, stroke, congestive heart failure, and mortality in an elderly cohort (the Cardiovascular Health Study)." Am J Cardiol, vol. 87, 2001, pp. 1051-1057.
[11] Post, W.S., et al. "Impact of left ventricular structure on the incidence of hypertension. The Framingham Heart Study." Circulation, vol. 90, 1994, pp. 179-185.
[12] Iso, H., et al. "Left ventricular mass and subsequent blood pressure changes among middle-aged men in rural and urban Japanese populations." Circulation, vol. 89, 1994, pp. 1717-1724.